Sermorelin — the classical GHRH 1-29 fragment, explained
Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). It was the first GHRH analog developed for clinical and research use, with the foundational work done by Roger Guillemin and colleagues in the late 1970s and clinical applications emerging in the 1980s. Sermorelin remains a reference compound against which newer GHRH analogs (tesamorelin, CJC-1295) are compared. Its short half-life — a limitation compared to the acylated analogs — is also a feature for research protocols that require pulsatile GH release. This primer covers the molecule, the GHRH 1-29 rationale, the regulatory history, and what distinguishes sermorelin in the current research toolkit.
The molecule. Sermorelin is a 29-amino-acid peptide with the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. Molecular weight is approximately 3,358 Da. The C-terminus is amidated, matching the native GHRH processing. The 1-29 fragment represents the minimum sequence retaining full GHRH-receptor binding affinity and biological activity — residues 30-44 of native GHRH contribute to serum stability and receptor-subtype selectivity but are not required for receptor engagement. This makes GHRH 1-29 the bioactive core and is why sermorelin occupies the central position in the GHRH-analog research landscape.
Discovery and early research. GHRH itself was isolated and characterized in 1982 by Guillemin's group (Nobel Prize 1977 for general hypothalamic-hormone research). The 1-29 active fragment was identified shortly after, and synthetic GHRH 1-29 was in clinical research by 1985. The foundational paper Thorner MO, Reschke J, Chitwood J, Rogol AD, Furlanetto R, Rivier J, Vale W, Blizzard RM. Acceleration of growth in two children treated with human growth hormone-releasing factor. N Engl J Med. 1985;312(1):4-9 (doi: 10.1056/NEJM198501033120102) is the first report of GHRH-analog treatment in children with GH deficiency. Subsequent work in the 1990s established sermorelin's PK profile, dose-response, and comparative behavior vs. direct GH administration.
Mechanism and pulsatile release. Sermorelin is a direct agonist at the GHRH receptor (GHRHR) on pituitary somatotrophs. Receptor engagement triggers cAMP-mediated growth-hormone release from pituitary stores. Sermorelin's half-life in humans is approximately 10-12 minutes — much shorter than the acylated GHRH analogs (tesamorelin ~25-40 min, CJC-1295 with DAC modification extended to several days). This short half-life is the central feature distinguishing sermorelin in research applications: it produces a sharp, self-limiting GH pulse that mimics the endogenous pulsatile release pattern, rather than a sustained elevation. Some research protocols — particularly those studying pulse-sensitive downstream targets — specifically prefer the classical 1-29 fragment for this reason.
Market history. Sermorelin's original US marketing authorization (Geref, Serono) was voluntarily withdrawn by Serono in 2008 for commercial reasons. Sermorelin remains in research and compounding-pharmacy use in the US. The withdrawal created the current landscape where tesamorelin — with a different, longer-half-life profile — is the more commonly referenced acylated GHRH analog, while sermorelin continues as the classical short-acting reference compound in research literature.
Research applications. Sermorelin research spans (1) pediatric GH-deficiency diagnostic and treatment protocols (the approved use) — these established the safety and pharmacodynamic baseline; (2) adult GH-axis research — dose-response studies, aging-related GH decline research, and body-composition research in older adults; (3) comparative-pharmacology research — sermorelin serves as the 'classical' reference when newer GHRH analogs (tesamorelin, CJC-1295 ± DAC) are characterized; (4) pulsatile-release research — protocols examining whether GH pulse pattern (vs. total GH exposure) drives specific downstream effects. The review Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-308 is a useful summary of the pre-2008 clinical-research landscape.
Administration routes and dose ranges. Research sermorelin administration is exclusively subcutaneous. Published protocols have used single-dose GH-secretion tests (0.3-1 mg) and chronic research dosing (typically 0.2-0.5 mg daily, bedtime administration). Bedtime dosing aligns with the endogenous nocturnal GH pulse and is the dominant research convention. The short half-life means daily dosing does not produce continuous receptor engagement — each dose creates a discrete pulse, which is a feature, not a limitation, for pulsatile-release research design.
Storage and handling. Sermorelin is less stable than the acylated GHRH analogs. Lyophilized powder is stable refrigerated (2-8 °C) for extended periods. Reconstituted solutions have limited in-use stability — classical clinical guidance was 28 days maximum at 2-8 °C with protection from light, which is the convention adopted for prefilled-pen formats. Vivaprime ships sermorelin at 2.5 mg/mL in a 3 mL pen, which reflects the appropriate clinical-protocol concentration for daily 0.2-0.5 mg dosing. Do not freeze.
What the COA should say. A batch-specific COA for sermorelin should include (1) identity by HPLC-MS matching the theoretical mass of approximately 3,358 Da (amidated C-terminus), (2) purity by reverse-phase HPLC ≥ 98% — sermorelin's impurity profile is well-characterized (deletion sequences, oxidation variants at Met28, deamidation variants), (3) endotoxin by LAL in EU/mg, (4) water content if lyophilized. Solid-phase peptide synthesis is the dominant production route.
Research-use only. Vivaprime supplies sermorelin as research reference material for qualified researchers engaged in in-vitro and research-context work. Sermorelin's active marketing authorization was withdrawn in the US in 2008; it remains approved in other markets and legal for compounding-pharmacy use under physician prescription. The research-grade material Vivaprime supplies is not supplied for compounding or patient care. Nothing on this page constitutes a therapeutic, diagnostic, or consumption recommendation. Purchasers affirm the research-use agreement at checkout. Related primers: [tesamorelin](/blog/tesamorelin-research-primer), [ipamorelin and CJC-1295](/blog/ipamorelin-cjc-1295-research-primer), [IGF-1 LR3](/blog/igf-1-lr3-research-primer).